A multicenter, open-label study for efficacy and safety evaluation of anagrelide in patients with treatment-naive, high-risk essential thrombocythemia as a primary treatment
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Byun, Ja Min | - |
dc.contributor.author | Kim, Ho Young | - |
dc.contributor.author | Nam, Seung-Hyun | - |
dc.contributor.author | Shin, Ho-Jin | - |
dc.contributor.author | Song, Seulki | - |
dc.contributor.author | Park, Jinny | - |
dc.contributor.author | Han, Sang Hoon | - |
dc.contributor.author | Park, Yong | - |
dc.contributor.author | Yuh, Young Jin | - |
dc.contributor.author | Mun, Yeung-Chul | - |
dc.contributor.author | Do, Young Rok | - |
dc.contributor.author | Sohn, Sang Kyun | - |
dc.contributor.author | Bae, Sung Hwa | - |
dc.contributor.author | Shin, Dong-Yeop | - |
dc.contributor.author | Yoon, Sung-Soo | - |
dc.date.accessioned | 2023-01-19T00:40:32Z | - |
dc.date.available | 2023-01-19T00:40:32Z | - |
dc.date.created | 2023-01-18 | - |
dc.date.issued | 2022-11 | - |
dc.identifier.issn | 2234-943X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/86657 | - |
dc.description.abstract | As the discussion of first-line anagrelide treatment is ongoing, we aimed to prospectively examine the efficacy and safety of anagrelide in cytoreduction therapy-naive high risk essential thrombocythemia (ET) patients in Korea. Seventy patients from 12 centers were treated with anagrelide monotherapy for up to 8 weeks, followed up until 24 months. At week 8, 50.0% of the patients were able to achieve platelet < 600 x 10(9)/L, and by 12 months, 55/70 (78.6%) patients stayed on anagrelide, and 40.0% patients showed platelet normalization. 14 patients required additional hydroxyurea (HU) for cytoreduction. The median daily dose of needed HU was 500mg (range 250mg - 1500mg). The efficacy was independent of the somatic mutation status. There were 4 thromboembolic events and 7 bleeding events during the follow-up period. The most common adverse events associated with anagrelide use were headache, followed by palpitation/chest discomfort, edema and generalized weakness/fatigue. 7 patients wished to discontinue anagrelide treatment due to adverse events (3 due to headache; 2 due to edema; 1 due to palpitation and 1 due to skin eruption). All in all, first-line anagrelide treatment showed a favorable response with tolerable safety profiles regardless of somatic mutation status. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | FRONTIERS MEDIA SA | - |
dc.relation.isPartOf | FRONTIERS IN ONCOLOGY | - |
dc.title | A multicenter, open-label study for efficacy and safety evaluation of anagrelide in patients with treatment-naive, high-risk essential thrombocythemia as a primary treatment | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000894079500001 | - |
dc.identifier.doi | 10.3389/fonc.2022.989984 | - |
dc.identifier.bibliographicCitation | FRONTIERS IN ONCOLOGY, v.12 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.scopusid | 2-s2.0-85143434726 | - |
dc.citation.title | FRONTIERS IN ONCOLOGY | - |
dc.citation.volume | 12 | - |
dc.contributor.affiliatedAuthor | Park, Jinny | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | essential thrombocythemia | - |
dc.subject.keywordAuthor | high risk | - |
dc.subject.keywordAuthor | Anagrelide | - |
dc.subject.keywordAuthor | phase IV clinical trial | - |
dc.subject.keywordAuthor | myeloproliferative neoplasms | - |
dc.subject.keywordPlus | POLYCYTHEMIA-VERA | - |
dc.subject.keywordPlus | HYDROXYUREA | - |
dc.subject.keywordPlus | MUTATION | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.